Harvey M. Golomb to Paclitaxel
This is a "connection" page, showing publications Harvey M. Golomb has written about Paclitaxel.
Connection Strength
0.418
-
Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-67-S12-69.
Score: 0.133
-
Clinical studies of docetaxel (Taxotere) and concomitant chest therapy. Semin Oncol. 1997 Aug; 24(4 Suppl 14):S14-26-S14-29.
Score: 0.133
-
Ifosfamide-based three-drug combination regimens in non-small cell lung cancer. Semin Oncol. 1998 Feb; 25(1 Suppl 2):19-22.
Score: 0.034
-
Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1998 Jan; 16(1):159-64.
Score: 0.034
-
Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies. Semin Oncol. 1996 Jun; 23(3 Suppl 6):11-5.
Score: 0.031
-
Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer. Semin Oncol. 1995 Aug; 22(4 Suppl 9):38-41.
Score: 0.029
-
A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer. Ann Oncol. 1998 Jun; 9(6):677-80.
Score: 0.009
-
Ifosfamide-based chemotherapy for non-small cell lung cancer: phase I/II studies at the University of Chicago. Semin Oncol. 1996 Jun; 23(3 Suppl 7):15-8.
Score: 0.008
-
Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: a phase I study. Ann Oncol. 1996 Mar; 7(3):314-6.
Score: 0.008